将投中网设为"星标⭐"，第一时间收获最新推送 硬科技赛道 ，"空天科技"成为新风口。 上周，北京穿越者载人航天科技有限公司正式宣布完成天使 +轮超募融资，由启迪之星创投加投。此外，追梦空天科技也在近日宣布连续完成两轮合计超亿元 Pre-A++轮及战略轮融资。Pre-A++轮融资由朝希资本领投，钧山资本、莫干山基金、海邦沣华等 机构跟投，老股东晓池资本持续跟投；战略轮融资由航投基金独家投资。 大健康赛道，合成生物学受青睐。 上周，合成生物学企业微远生物已成功完成近亿元Pre-A轮融 资。本轮融资由熔拓资本领投，道彤投资跟投，种子轮老股东大晶创投、真石资本持续坚定追加投 资。与此同时，合成生物学企业苏州一兮生物宣布完成近2亿元A轮融资，本轮融资由黄山新安江资 本投资管理有限公司管理的黄山供赢一兮股权投资基金投资。 互联网赛道，AI投资聚焦"应用层"。 上周，情感语音交互模型初创公司宇生月伴近日完成新一轮融 资，由靖亚资本和小苗朗程领投，菡源资产（上海交大母基金）跟投，心流资本FlowCapital担任长 期财务顾问。此外，ChatExcel 团队近日已完成近千万天使轮融资。此次融资由上海常垒资本、武 汉东湖天使基 ...

Core Viewpoint - The establishment of the "Shenzhen University-Ningbo Enzyme Bioengineering Co., Ltd. Joint Laboratory for Computational Protein" marks a significant collaboration aimed at advancing AI-driven synthetic biology research and its industrial applications in pharmaceuticals, energy, and agriculture [1][4][6]. Group 1: Joint Laboratory Focus - The joint laboratory will focus on AI-driven synthetic biology research, emphasizing protein design and optimization, high-performance industrial enzyme development, and the application of these technologies in various industries [4][5]. - Key research directions include computational protein design, computer simulation and intelligent optimization of biosynthetic pathways, and talent cultivation in AI-integrated enzyme engineering [5][6]. Group 2: Industry Impact - The introduction of AI technology is expected to revolutionize traditional research methods in protein design, metabolic engineering, and biosynthesis, aiming to create a programmable and scalable intelligent bio-manufacturing platform [6]. - The collaboration is seen as a model for industry-academia cooperation, leveraging the research strengths of Shenzhen University and the industrial capabilities of Ningbo Enzyme Bioengineering to promote practical applications of synthetic biology [6][7]. Group 3: Company Background - Shenzhen University, established as a new research-oriented institution in 2024, focuses on foundational and cutting-edge scientific research and the cultivation of innovative talents [6][7]. - Ningbo Enzyme Bioengineering Co., Ltd. is a leading synthetic biology company in China, possessing proprietary technologies in protein design and enzyme engineering, with capabilities spanning from laboratory research to industrial production [7]. Group 4: Future Prospects - The collaboration signifies a new phase in AI-driven bio-manufacturing, contributing to the high-quality development of China's bio-economy [8].

Core Viewpoint - The article discusses the collaboration between the Ministry of Industry and Information Technology and the National Health Commission to promote innovative biomanufacturing technologies in the food processing sector, aiming to enhance the industrialization and marketization of research outcomes [2][3]. Group 1: Policy and Application Directions - The initiative focuses on collecting innovative biomanufacturing technology applications in areas such as food raw materials, food additives, and food and beverage processing [3]. - The application directions should align with the goal of building a diversified food supply system and have significant promotional value for industry development [3][4]. - Relevant products must be domestically developed, have completed small-scale pilot production or be in large-scale production, and demonstrate safety through research or prior approvals in other regions [4]. Group 2: Submission and Evaluation Process - Entities eligible for recommendation include registered companies, universities, research institutions, and industry associations with good biomanufacturing capabilities and no major safety or environmental incidents in the past three years [5]. - Recommended units must submit a detailed application form along with supporting materials by September 15, 2025, to the Ministry of Industry and Information Technology [6][7]. - The Ministry will organize experts to evaluate the submissions and identify key application directions that are strategically significant, technologically advanced, and have broad application prospects [8]. Group 3: SynBioCon 2025 Conference - The fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22, 2025, in Ningbo, Zhejiang, focusing on AI and biomanufacturing, green chemicals and new materials, future food, and future agriculture [9][10]. - The conference will include various activities such as a youth forum, high-level discussions, and a closed-door seminar on AI-enabled biomanufacturing innovation [9][10]. - The event aims to explore the development trends and growth points of biomanufacturing during the 14th Five-Year Plan period [22].

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and resource security, as highlighted in the "14th Five-Year Plan for Bioeconomic Development" issued by the National Development and Reform Commission [4] - The Huazhong Securities Synthetic Biology Index, which includes 58 companies involved in synthetic biology, decreased by 5.72% to 1549.03 during the week of August 4-8, 2025, while the Shanghai Composite Index rose by 2.11% [5][19] - The report emphasizes the significance of newly announced pilot projects for green liquid fuels, which aim to enhance energy security and promote green transformation in the energy sector [10] Summary by Sections 1. Synthetic Biology Market Dynamics - The synthetic biology sector's stock performance for the week of August 4-8, 2025, saw an overall decline of 5.72%, ranking 32nd among various sectors [19] - The top five gainers in the synthetic biology field included Hanyu Pharmaceutical (+17%), Jinzi Ham (+9%), and Meiyingsen (+8%) [20] - The top six decliners included Yab Chemical (-8%), Te Bao Biological (-6%), and Baiji Shenzhou (-6%) [21] 2. Company Business Developments - Agilent and Yikela Bio established a joint innovation laboratory focused on high-throughput synthetic biology design and screening [26] - Zhuhai Wantong's project for producing 40,000 tons of bio-based high-temperature nylon is undergoing environmental impact assessment [27] - Algenesis Labs launched the world's first 100% plant-based isocyanate production facility in California [28] 3. Industry Financing Tracking - Financing activities in the synthetic biology sector have accelerated, with companies like Leaf Bio completing significant funding rounds [33] - Chai Discovery raised $70 million in Series A funding to enhance AI-driven drug discovery processes [33]

Core Viewpoint - The article highlights the advancements in synthetic biology for the production of functional lipids, showcasing the innovative research led by Professor Huang He from Nanjing Normal University and the Jiangsu Provincial Synthetic Biology Research Center [2][10][14]. Group 1: Importance of Synthetic Biology - Synthetic biology is described as a field that reprograms life, utilizing engineering methods and gene editing to transform microorganisms into efficient production "factories" for useful compounds [11][12]. - The integration of synthetic biology with clean technology offers innovative solutions to global challenges, especially with the advent of CRISPR and other gene editing tools [12]. Group 2: Role of Artificial Intelligence - Artificial intelligence (AI) is crucial in the development of synthetic biology, enabling systematic programming of biological components and significantly reducing the development time of microbial "factories" from years to months [13]. - The combination of machine learning and CRISPR technology optimizes microbial metabolic pathways, revolutionizing industrial biotechnology [13]. Group 3: Focus on Functional Lipids - The shift in dietary patterns, with a decrease in carbohydrate consumption and an increase in fat intake, underscores the importance of lipid metabolism in health and disease, prompting a focus on functional lipids, particularly unsaturated fatty acids [11]. - Traditional extraction methods for functional lipids from fish are limited by high costs and lengthy supply chains, leading to research on engineered lipid production for cost reduction and sustainable practices [11]. Group 4: Achievements and Innovations - The research team has successfully constructed a cell factory using synthetic biology methods, achieving over a twofold increase in fatty acid yield and reducing research and development time significantly [11]. - A high-throughput screening platform was developed, increasing efficiency by over ten times, reducing extraction time from three days to three hours, and cutting costs by 80% [11]. Group 5: Future Plans - Future research will explore the synthesis of functional lipids from purified components, aiming to combine various beneficial ingredients for health management [11]. - The goal includes designing formulations that integrate functional components, such as carotenoids for vision enhancement and other ingredients for brain health [11]. Group 6: Unique Advantages of the Research Center - The Jiangsu Provincial Synthetic Biology Research Center, established in 2023, focuses on industrial biological manufacturing, bridging basic science and applied research [12][14]. - The center promotes interdisciplinary exploration and engineering solutions, providing early-career researchers with autonomy and reducing administrative barriers to collaboration [12]. Group 7: Collaboration and Impact - The center collaborates with major enterprises like the National Development Investment Corporation to connect market demands with scientific breakthroughs and result transformations [14]. - The recent feature in the prestigious journal Nature highlights Professor Huang He's international academic influence in the field [14].

SynBio团队 | 天工所李德茂 檀香精油，源于檀香木心材，以其深邃、温暖、持久的独特木香气，被誉为 " 液体黄金 " ，位列世界最顶级的天然 香料之一。其核心价值成分檀香醇在香水、化妆品、医药和宗教仪式中需求巨大。然而，檀香木生长缓慢（需数十年 成材），资源稀缺且过度采伐导致价格极其昂贵（市场价约 2500 美元 / 公斤），供应极不稳定。利用合成生物学 构建微生物 " 芳香本草细胞 " ，实现檀香精油等香精香料的可持续、规模化发酵生产，是解决资源瓶颈、保障稳定 供应的理想途径，前期该研究团队成功创建的 " 玫瑰精油酵母 " 已经进入产业化阶段。 【SynBioCon】 获 悉 ， 近日， 中国科学院天津工业生物技术研究所 戴住波、张学礼 研究 团队 在 《 Journal of Agricultural and Food Chemistry 》 上发表重要研究成果。该研究运用 亚细胞区室工程 策略，聚焦于 过氧化物 酶体（ Peroxisome ） 的改造与利用， 开发 P450 酶过氧化物酶体表面展示技术 ， 解决了 该途径中细胞色素 P450 酶的催化瓶颈， 成功构建了高效生产 檀香醇 的酵母细胞工 ...

蓝晶微生物 建立了自动化数字化的黑灯实验室研发平台，利用合成生物技术不断迭代增效剂生物制造的菌株和工艺，开发了一系列 新型植物刺激素 的工业化合成技术，以解决农业生产中未被满足的需求。 如2024年11月，蓝晶微生物首个面向农业市场的 多生菌脂（PHA）产品矩阵 。 这款产品主要针对农业，是一种能 有效激活根际微生物的天然物质 。 来源：蓝晶微生物 其产品矩阵包括 蓝多丰™ 微生物菌剂、多生元™ 有机水溶肥料、根际蓝™ 含氨基酸水溶肥料等 。这些产品从增产提质的实际功效出发，围绕不同 场景、不同作物的差异化需求，为农业用户和合作伙伴提供全方位、精准化支持，共同推动农业绿色健康发展迈向新高度。 点击更多阅读 ： 蓝晶微生物，正式进军农业赛道！ SynBioCon 大会 | 蓝晶微生物 农业是我国的基础产业，提升农业单产需要底层技术创新带来的新质生产力，合成生物技术可以提供生长刺激、生物防控、生物肥料等绿色农业增效 剂。 对此， 蓝晶微生物首席科学家 饶驰通 将出席 8 月20-22日 在 浙江·宁波 举办的 SynBioCon 2025 第四届合成生物绿色生物制造大会 「未来 食品&农业 」专 场 分 享以 《 ...

Focus Review - The hard technology sector is witnessing significant early-stage financing, with Shanghai Fangqing Technology recently completing several hundred million RMB in angel round financing led by Xiaomi's strategic investment department, followed by investments from NIO Capital and Ming Shi Capital [4][13] - In the health sector, synthetic biology continues to attract attention, with Yinhang Biotechnology completing over 100 million RMB in a new financing round, backed by multiple investment firms including CICC Capital and Xingxiang Capital [20] - The internet sector, particularly in AI applications for marketing and customer service, is gaining traction, as evidenced by Reindeer AI's recent tens of millions RMB A+ round financing led by Kunyan Capital and IDG [29] Hard Technology - RoboScience announced nearly 200 million RMB in angel round financing, led by JD.com, with participation from several other investment firms [14] - Taihu Xingyun, a company in the commercial aerospace sector, completed over 50 million RMB in A round financing, led by the Wuxi Liangxi District Science and Technology Innovation Industry Investment Fund [11] - Nova Fusion achieved 500 million RMB in angel round financing, marking a record for private nuclear fusion companies in China, with participation from various capital and state-owned funds [17] Health Sector - Orange Sail Medicine completed over 60 million USD in Pre-A+ round financing, led by Shunwei Capital, with participation from several other investment firms [19] - Yikole Biotechnology secured a strategic investment of 450 million RMB from multiple funds, including the Jutou Mergers and Acquisitions Fund [23] - Puliyan Medical Technology announced nearly 300 million RMB in C round financing, with investments from several notable firms [26] Internet/Enterprise Services - Mingqi Home secured strategic investment from Oriza FoFs and FountainVest [28] - Reindeer AI completed tens of millions RMB in A+ round financing, with Kunyan Capital and IDG leading the investment [29] - Xiaojiyun (Hainan) Smart Technology Co., Ltd. announced 10 million RMB in angel round financing, exclusively from Zhongliang Huatai Investment [31]

Core Viewpoint - The second Synthetic Biology and Intelligent Bio-Manufacturing Academic Exchange Conference was held from August 4 to 6, highlighting the growing interest in synthetic biology and its applications in various industries [1] Industry Summary - CITIC Securities expresses optimism about the long-term development of new raw materials in synthetic biology, indicating significant potential in the development of new raw materials for food, health products, and cosmetics [1] - The maturity of technologies such as chassis cell libraries, component libraries, high-throughput screening platforms, and rapid chassis cell development capabilities is contributing to a steep decline in the cost of new raw materials, facilitating faster market adoption [1]

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. is planning to issue overseas shares (H shares) and list on the Hong Kong Stock Exchange to enhance its global development strategy and brand influence [2][3]. Group 1: Company Overview - Huaheng Biological was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 22, 2021, with a current market value of approximately 8.35 billion RMB [5]. - The company specializes in the research, production, and sales of bio-based products, focusing on synthetic biology technology [6]. Group 2: Product and Market Position - Huaheng Biological is a leading producer of amino acid products, ranking first globally in the production and sales of alanine and valine [7]. - The company is expanding its product line to include bio-based chemicals such as 1,3-propanediol, succinic acid, and L-malic acid, while also investing in related startups [7]. Group 3: Recent Developments - In June 2023, Huaheng Biological planned to raise no more than 1.689 billion RMB for the construction of production bases for bio-based succinic acid and bio-based apple acid, each with an annual capacity of 50,000 tons [7]. - The company has established partnerships with various institutions, including a joint laboratory with Donghua University to advance the development of bio-based chemical fiber technology [10]. Group 4: Industry Events - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22, 2025, in Ningbo, focusing on AI in bio-manufacturing and green chemistry [17][19]. - The conference will include discussions on the development trends of the bio-manufacturing industry and the role of AI in driving innovation [39].